Physician profile
John Charles Affeldt
NPI 1275523375
$1,101,081.92
in general payments reported to CMS, 2019-2025
18 companies · $258K in 2025
The $258K reported for 2025 was more than what 99% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $109K · 2020: $19K · 2021: $191K · 2022: $179K · 2023: $102K · 2024: $243K · 2025: $258K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $286K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $196K · Travel and Lodging: $65K · Consulting Fee: $41K · Food and Beverage: $15K · Education: $128.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $285,525.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $196,487.43 |
| Travel and Lodging | $64,922.46 |
| Consulting Fee | $41,227.50 |
| Food and Beverage | $15,150.60 |
| Education | $128.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $528,164.73 | 2020-2025 | Acthar |
| Dompe US, INC. | $253,625.41 | 2019-2025 | Oxervate |
| Bausch & Lomb Americas INC. | $97,599.59 | 2022-2025 | Miebo, Xiidra, Blink Nutritears |
| Mallinckrodt Enterprises LLC | $72,296.68 | 2019 | |
| Kala Pharmaceuticals, INC. | $43,127.44 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $41,425.02 | 2020-2025 | Cequa |
| Alcon Vision LLC | $32,512.55 | 2022-2025 | Tryptyr, Eysuvis, Rocklatan |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $23,260.96 | 2019-2021 | |
| Eyevance Pharmaceuticals LLC | $7,073.40 | 2019-2022 | |
| Oyster Point Pharma, INC. | $642.82 | 2022-2023 | Tyrvaya |
| Allergan, INC. | $601.93 | 2019-2022 | |
| Harrow Eye, LLC | $322.17 | 2024-2025 | Vevye |
| Biotissue Holdings INC. | $238.96 | 2023-2025 | |
| Shire North American Group INC | $91.38 | 2019 | |
| Novartis Pharmaceuticals Corporation | $61.18 | 2019-2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $23.53 | 2025 | Tepezza |
| Halozyme INC | $14.17 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Affeldt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.